Fashedemi Y, Coutts M, Wise O, Bonhomme B, Baker G, Kelly PJ, Soubeyran I, Catherwood MA, Croce S, McCluggage WG (2019) Adult granulosa cell tumor with high-grade transformation: report of a series with FOXL2 mutation analysis. Am J Surg Pathol 43:1229–1238. https://doi.org/10.1097/PAS.0000000000001296

Article  PubMed  Google Scholar 

Sakr S, Abdulfatah E, Thomas S, Al-Wahab Z, Beydoun R, Morris R, Ali-Fehmi R, Bandyopadhyay S (2017) Granulosa cell tumors: novel predictors of recurrence in early-stage patients. Int J Gynecol Pathol 36:240–252. https://doi.org/10.1097/PGP.0000000000000325

Article  PubMed  PubMed Central  Google Scholar 

Balan RA, Caruntu ID, Giusca SE, Lozneanu L, Pavaleanu I, Socolov RV, Miron L, Marinca MV, Amalinei C (2017) Immunohistochemical significance of ER alpha, inhibin A, calretinin, and Ki67 expression in granulosa cell ovarian tumors. Rom J Morphol Embryol 58:753–760

PubMed  Google Scholar 

Alexiadis M, Rowley SM, Chu S, Leung DTH, Stewart CJR, Amarasinghe KC, Campbell IG, Fuller PJ (2019) Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing. Mol Cancer Res 17:177–185. https://doi.org/10.1158/1541-7786.MCR-18-0359

Article  CAS  PubMed  Google Scholar 

McConechy MK, Farkkila A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, Yang W, Rozenberg N, Andersson N, Zaby K, Bryk S, Butzow R, Halfwerk JB, Hooijer GK, van de Vijver MJ, Buist MR, Kenter GG, Brucker SY, Kramer B, Staebler A, Bleeker MC, Heikinheimo M, Kommoss S, Blake Gilks C, Anttonen M, Huntsman DG (2016) Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype. J Natl Cancer Inst 108. https://doi.org/10.1093/jnci/djw134

Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360:2719–2729. https://doi.org/10.1056/NEJMoa0902542

Article  CAS  PubMed  Google Scholar 

Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Clement PB, Gilks CB, Huntsman DG, Kommoss F (2019) DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumors. Am J Surg Pathol 43:628–638. https://doi.org/10.1097/PAS.0000000000001232

Article  PubMed  Google Scholar 

McCluggage WG, Soslow RA, Gilks CB (2011) Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance. Histopathology 59:786–788. https://doi.org/10.1111/j.1365-2559.2011.03907.x

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738

Article  CAS  PubMed  Google Scholar 

Li X, Tian B, Liu M, Miao C, Wang D (2022) Adult-type granulosa cell tumor of the ovary Am. J Cancer Res 12:3495–3511

CAS  Google Scholar 

Puechl AM, Edwards J, Suri A, Nakayama J, Bean S, Gehrig P, Saks E, Duska L, Broadwater G, Ehrisman J, Horowitz N, Secord AA (2019) The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. Gynecol Oncol 153:74–79. https://doi.org/10.1016/j.ygyno.2019.01.016

Article  CAS  PubMed  Google Scholar 

Krishnamurthy N, Nishizaki D, Lippman SM, Miyashita H, Nesline MK, Pabla S, Conroy JM, DePietro P, Kato S, Kurzrock R (2024) High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Ther Adv Med Oncol 16:17588359231220510. https://doi.org/10.1177/17588359231220510

Article  PubMed  PubMed Central  Google Scholar 

Mills AM, Chinn Z, Rauh LA, Dusenbery AC, Whitehair RM, Saks E, Duska LR (2019) Emerging biomarkers in ovarian granulosa cell tumors. Int J Gynecol Cancer 29:560–565. https://doi.org/10.1136/ijgc-2018-000065

Article  PubMed  Google Scholar 

Kassardjian A, Shintaku PI, Moatamed NA (2018) Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLoS One 13:e0195958. https://doi.org/10.1371/journal.pone.0195958

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lan G, Li J, Wen Q, Lin L, Chen L, Chen L, Chen X (2018) Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncol Lett 15:5093–5097. https://doi.org/10.3892/ol.2018.7991

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T (2017) CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother 66:1449–1461. https://doi.org/10.1007/s00262-017-2039-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, Polito L, Ratta M, Pileri S, Piccioli M, Basso G, Rissotto L, Conte R, Gobbi M, Stirpe F, Ferrara GB (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101:202–209. https://doi.org/10.1182/blood-2002-06-1668

Article  CAS  PubMed  Google Scholar 

Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550. https://doi.org/10.1002/ijc.21155

Article  CAS  PubMed  Google Scholar 

Karpathiou G, Chauleur C, Mobarki M, Peoc’h M (2020) The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. Pathol Res Pract 216:152782. https://doi.org/10.1016/j.prp.2019.152782

Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP (2012) Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 61:1463–1472. https://doi.org/10.1007/s00262-012-1211-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC (2016) Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget 7:26670–26679. https://doi.org/10.18632/oncotarget.8476

Article  PubMed  PubMed Central  Google Scholar 

Higgins PA, Brady A, Dobbs SP, Salto-Tellez M, Maxwell P, McCluggage WG (2014) Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours. Histopathology 64:633–638. https://doi.org/10.1111/his.12322

Article  PubMed  Google Scholar 

Kusamura S, Derchain S, Alvarenga M, Gomes CP, Syrjanen KJ, Andrade LA (2003) Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary. Int J Gynecol Cancer 13:450–457. https://doi.org/10.1046/j.1525-1438.2003.13327.x

Article  CAS  PubMed  Google Scholar 

Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H, Moinfar F (2006) Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol 101:18–23. https://doi.org/10.1016/j.ygyno.2005.10.009

Article  CAS  PubMed  Google Scholar 

Menczer J, Schreiber L, Czernobilsky B, Berger E, Golan A, Levy T (2007) Is Her-2/neu expressed in nonepithelial ovarian malignancies? Am J Obstet Gynecol 196(79):e71-74. https://doi.org/10.1016/j.ajog.2006.07.050

Article  CAS  Google Scholar 

Farkkila A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, Unkila-Kallio L (2014) HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med 3:526–536. https://doi.org/10.1002/cam4.230

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753–3758. https://doi.org/10.1158/1078-0432.CCR-18-4070

Article  CAS  PubMed